Fabrazyme 2017 U.S. Promotional Audit Report - ResearchAndMarkets.com

The "Fabrazyme 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering.

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Fabrazyme through reportable promotional activity in 2017 to drive use within the Fabry's Disease market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
• How does Sanofi's depth of coverage vary within key specialties (e.g., Nephrology, Optometry, Internal Medicine, Neurology, and Cardiology) and how does this compare to the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Fabrazyme throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Fabrazyme in 2017?

Data Sources and Methodology:

• The author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available - covering payments to more than 975,000 U.S. healthcare professionals.
• Over 1,500 paid interactions across 1,100 physicians made on behalf of Fabrazyme were carefully examined to support our analysis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180912006054/en/